Catalent Pharma Solutions is betting big on the Chinese market, launching two joint ventures for its Softgel Technologies and Clinical Supply Solutions businesses. In the first, it will acquire a majority stake in Zhejiang Jiang Yuan Tang Biotechnology, which produces softgels, and in the second, it will partner with ShangPharma to provide clinical trial supplies in China. Catalent isn't disclosing financial details in either deal. More